On August 28, 2026, Pfizer Inc (NYSE: PFE) announced the FDA approval of Lisraya (brepocitinib), its lead drug for treating dermatomyositis, marking a significa...
Market Samachar is a news aggregator. This article was originally published by gurufocus.com. Tap the button above to read the full story on their site.